20/20 Biolabs, Inc.

AIDX

Nasdaq; other; SIC 8734, Services-Testing Laboratories; CIK 0001139685


None

No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $4.1M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	late filer, thin data not computable: dilution, short runway, distress, fortress balance sheet
Inputs computable	3 of 14
Graded from	filings received through Mar 31, 2026 226 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$0.22 2026-11-11; market equity $2.9M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that was launched in February 2026 (the Longevity test is also being branded "OneTest for Workplace Wellness" when marketed to self-insured employers). Both tests are run in our CAP (College of American Pathologists) accredited, CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory in Gaithersburg, MD.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 71.3						
Gross profitability	14.6%	27.0%		71.3	287	2025-12-31
Return on invested capital	not computable	10.0%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	not computable	(5.8%)				
a prior annual assets observation is required						
Gross margin stability, five years	not computable	2.2 pts				
five annual gross margins are required; found 1						
Solvency, sleeve percentile 91.2						
Twelve-month failure probability	not computable	0.04%				
four consecutive discrete net-income quarters are required; found 2						
Altman Z double-prime	(33.18)	2.05		96.9	390	2025-12-31
Net debt to EBITDA	not computable	2.51x				
one or more required annual facts are missing						
Interest coverage	not computable	2.45x				
one or more required annual facts are missing						
Current ratio	0.60x	1.33x		85.5	510	2025-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	5.0%				
four annual observations are required; found 1						
Free cash flow growth, three-year compound	not computable	8.9%				
four consecutive annual FCF observations are required; found 0						
Reinvestment rate	not computable	12.2%				
one or more required annual facts are missing						
Asset growth, three years	not computable	4.0%				
four annual observations are required; found 1						
Net share issuance, one year	not computable	(0.5%)				
two annual share counts are required; found 1						

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	3 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-11 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	not computable	(1.0%)	
Distance from 52-week high	(99.1%)	(22.0%)	1
EBIT to enterprise value	not computable	4.2%	
Free cash flow yield	not computable	4.1%	
Book value to price	0.56	0.34	74
Sales to price	0.71	0.68	52
Composite equity issuance, five years	not computable	(8.8%)	
Relative strength against the sector, log excess return	not computable	(0.13)	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	90 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$28,688

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$604,541	2025-12-31	2026-03-31	10-K	26-037667
2	assets	us-gaap:Assets	$4.1M	2025-12-31	2026-03-31	10-K	26-037667
3	net income	us-gaap:NetIncomeLoss	-$3.7M	2025-12-31	2026-03-31	10-K	26-037667
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$1.9M	2025-12-31	2026-03-31	10-K	26-037667
5	current assets	us-gaap:AssetsCurrent	$1.5M	2025-12-31	2026-03-31	10-K	26-037667
6	current liabilities	us-gaap:LiabilitiesCurrent	$2.5M	2025-12-31	2026-03-31	10-K	26-037667
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$33.2M	2025-12-31	2026-03-31	10-K	26-037667
8	operating income	us-gaap:OperatingIncomeLoss	-$3.3M	2025-12-31	2026-03-31	10-K	26-037667
9	book equity	us-gaap:StockholdersEquity	-$19,225	2025-12-31	2026-03-31	10-K	26-037667
10	liabilities	us-gaap:Liabilities	$4.2M	2025-12-31	2026-03-31	10-K	26-037667
11	revenue	us-gaap:Revenues	$2.0M	2025-12-31	2026-03-31	10-K	26-037667
12	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,442,960	2026-03-30	2026-03-31	10-K	26-037667

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.